Shares of Aptevo Therapeutics Inc. (APVO), a clinical-stage research and development biotechnology company, are up over 80% at $2.55 in pre-market trading on Thursday.
Early this week, the company announced a 100% remission rate in Cohort 3 of its Phase 1b/ 2 RAINIER trial, along with no dose-limiting toxicities or cytokine release syndrome observed to date.
RAINIER is a Phase 1b/2 dose optimization, multi-center, multi-cohort trial evaluating the drug candidate Mipletamig, a bispecific antibody, in combination with Venetoclax and Azacitidine for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy.
For comments and feedback contact: editorial@rttnews.com
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.